Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma
Authors
Keywords
Cancer treatment, Surgical and invasive medical procedures, Hepatectomy, Surgical oncology, Differentiated tumors, Hepatocellular carcinoma, Metastasis, Histology
Journal
PLoS One
Volume 13, Issue 9, Pages e0203856
Publisher
Public Library of Science (PLoS)
Online
2018-09-15
DOI
10.1371/journal.pone.0203856
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients
- (2017) Daimin Xiang et al. HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma
- (2017) Karim Chamie et al. JAMA Oncology
- Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells
- (2016) Yan Lu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Genetic profiling of hepatocellular carcinoma using next-generation sequencing
- (2016) Kornelius Schulze et al. JOURNAL OF HEPATOLOGY
- Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
- (2015) Jessica Zucman-Rossi et al. GASTROENTEROLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Clinicopathological indices to predict hepatocellular carcinoma molecular classification
- (2015) Poh Seng Tan et al. LIVER INTERNATIONAL
- Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use
- (2015) Jaromir Pastorek et al. SEMINARS IN CANCER BIOLOGY
- Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics
- (2015) Paul C. McDonald et al. Oncotarget
- YAP activation is an early event and a potential therapeutic target in liver cancer development
- (2014) Andrea Perra et al. JOURNAL OF HEPATOLOGY
- Clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatoce
- (2012) Hideki Ijichi et al. HEPATOLOGY RESEARCH
- Triple Positive Tumor Markers for Hepatocellular Carcinoma Are Useful Predictors of Poor Survival
- (2011) Shigehisa Kiriyama et al. ANNALS OF SURGERY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features
- (2008) Taro Yamashita et al. GASTROENTEROLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search